What are the effects of Glucagon-like peptide-1 (GLP-1) treatment on chronic diarrhea?
NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or above alongside at least one weight-related condition, within a specialist weight management service (with lower BMI thresholds applicable for certain ethnic groups and other commissioning criteria)
This delayed stomach emptying creates feelings of fullness and reduces appetite, which drives weight loss
It supports healing it doesn't replace rest, rehab, sleep, and protein intake
Rodriguez 2025 (EHR, n=125,474): 1-year discontinuation 64.8% in non-diabetics vs 46.5% in type 2 diabetes
Cancer 41 , 28732881 (2005)